Bono Raquel C. has officially filed a Form 3 with the SEC, confirming her position as a director at Vaxart, Inc. This filing is significant as it showcases her involvement in the company and highlights the regulatory compliance within the biological products industry.
Background
Vaxart, Inc. operates within the biological products sector, specifically focusing on products that do not include diagnostic substances. The company is incorporated in Delaware and has its headquarters located at 310 Utah Avenue, Suite 150, South San Francisco, CA. The company has undergone several name changes in the past, including its former name, Aviragen Therapeutics, Inc., which it adopted in April 2016.
What the Filing Says
The Form 3, filed on October 20, 2026, indicates that Bono Raquel C. holds one security in Vaxart, Inc. The filing specifies, "Exhibit 24 - Power of Attorney," which suggests that she has granted authority to certain individuals to act on her behalf regarding SEC reporting purposes.
Impact
This filing may affect various stakeholders, including investors, regulatory bodies, and other directors within Vaxart, Inc. It emphasizes the importance of transparency and compliance in the life sciences industry, where regulatory scrutiny is high.
What's Next
The filing does not say what happens next.